Evans syndrome future or investigational therapies

Evans syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Evans syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Evans syndrome future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Evans syndrome future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Evans syndrome future or investigational therapies
CDC on Evans syndrome future or investigational therapies
Evans syndrome future or investigational therapies in the news
Blogs on Evans syndrome future or investigational therapies
Directions to Hospitals Treating Evans syndrome
Risk calculators and risk factors for Evans syndrome future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Future or Investigational Therapies

In a patient with refractory disease, an allogeneic hematopoietic stem cell transplant (HSCT) resulted in complete clinical and serologic remission for more than 30 months. Allogeneic HSCT may be the only current curative therapy for Evans syndrome, but may also be complicated by significant toxicities. In more serious cases no cure exists.